Azenta announces collaboration with the crohn's & colitis foundation to support its crohn's disease and ulcerative colitis clinical research

Azenta has been selected by the crohn's & colitis foundation as its sample management services provider for its inflammatory bowel disease (ibd) capture and sirqc clinical registries burlington, mass. , june 4, 2024 /prnewswire/ -- azenta, inc. (nasdaq: azta) today announced it has been selected by the crohn's & colitis foundation (the "foundation") as its sample management services provider for two of its large-scale prospective research cohorts, capture ibd and ibd sirqc, which investigate pediatric and surgical care for crohn's disease and ulcerative colitis.
AZTA Ratings Summary
AZTA Quant Ranking